BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22037226)

  • 1. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.
    Petersen J; Ratziu V; Buti M; Janssen HL; Brown A; Lampertico P; Schollmeyer J; Zoulim F; Wedemeyer H; Sterneck M; Berg T; Sarrazin C; Lutgehetmann M; Buggisch P
    J Hepatol; 2012 Mar; 56(3):520-6. PubMed ID: 22037226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.
    Si-Ahmed SN; Pradat P; Zoutendijk R; Buti M; Mallet V; Cruiziat C; Deterding K; Dumortier J; Bailly F; Esteban R; Wedemeyer H; Janssen HL; Zoulim F
    Antiviral Res; 2011 Oct; 92(1):90-5. PubMed ID: 21767570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Pan CQ; Hu KQ; Yu AS; Chen W; Bunchorntavakul C; Reddy KR
    J Viral Hepat; 2012 Mar; 19(3):213-9. PubMed ID: 22329376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
    Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y
    Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment.
    Ozaras R; Mete B; Ceylan B; Ozgunes N; Gunduz A; Karaosmanoglu H; Cagatay A; Gokturk K; Erdem L; Kocak F; Senates E; Tabak F
    Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):774-80. PubMed ID: 24901822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
    Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
    Buti M; Brosa M; Casado MA; Rueda M; Esteban R
    J Hepatol; 2009 Oct; 51(4):640-6. PubMed ID: 19576651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
    J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.
    Gish RG; Clark MD; Kane SD; Shaw RE; Mangahas MF; Baqai S
    Clin Gastroenterol Hepatol; 2012 Aug; 10(8):941-6; quiz e68. PubMed ID: 22507876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir therapy for lamivudine resistance following liver transplantation.
    Neff GW; Nery J; Lau DT; O'Brien CB; Duncan R; Shire NJ; Ruiz P; Nery C; Montalbano M; Muslu H; Safdar K; Schiff ER; Tzakis AG; Madariaga JR
    Ann Pharmacother; 2004 Dec; 38(12):1999-2004. PubMed ID: 15507498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.
    Jeng WJ; Sheen IS; Chen YC; Hsu CW; Chien RN; Chu CM; Liaw YF
    Hepatology; 2013 Dec; 58(6):1888-96. PubMed ID: 23744454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders.
    Yip B; Chaung K; Wong CR; Trinh HN; Nguyen HA; Ahmed A; Cheung R; Nguyen MH
    Dig Dis Sci; 2012 Nov; 57(11):3011-6. PubMed ID: 23010744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.